No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
RBC Capital Maintains 89bio(ETNB.US) With Hold Rating, Maintains Target Price $12
Analysts Offer Insights on Healthcare Companies: 89bio (ETNB), Gain Therapeutics (GANX) and Boston Scientific (BSX)
Goldman Sachs Initiates 89bio(ETNB.US) With Hold Rating, Announces Target Price $11
Goldman Sachs Initiates Coverage On 89bio With Neutral Rating, Announces Price Target of $11
89bio (ETNB) Receives a New Rating From Goldman Sachs
Citi Maintains 89bio(ETNB.US) With Buy Rating, Cuts Target Price to $25